
    
      Two hundred to three hundred subjects (equally distribued between placebo and D-ribose)
      between 18-78 years of age will comprise this study. The final numbers enrolled will depend
      upon obtaining approximately 100 subjects that can display a high degree of compliance to TID
      dosing with approximately equal balance between the active and placebo arms.
    
  